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General Introduction and Scope of the Thesis
Global burden of Dengue virus and Chikungunya virus
 Dengue virus (DENV) and Chikungunya virus (CHIKV) are rapidly 
emerging single-stranded positive-sense RNA viruses that are prevalent in the 
tropical and subtropical regions of world (figure 1). Both viruses are transmitted 
to humans by mosquitoes of the Aedes (Ae.) species, with the yellow fever mosquito 
(Ae. aegypti) and the tiger mosquito (Ae. albopictus) being the main vectors [1-3]. 
 
 The incidence of DENV increased more than 30-fold over the last 60 years due 
to large scale unplanned urbanization, international trade and travel, and population 
growth [1,4]. Accordingly, DENV is the most rapidly spreading and also most 
common mosquito-borne viral infection worldwide. Yearly, an estimated 390 million 
individuals are infected with DENV and about 100 million develop symptomatic 
disease [5]. Four serotypes of DENV have been described (DENV-1 to 4) and each of 
them can cause symptomatic disease. Disease is classified in three categories: “dengue 
without warning signs”, “dengue with warning signs”, and “severe dengue”. In most 
cases, dengue is mild with symptoms including fever, rash, muscle and joint pain, and 
nausea. Patients that have additional symptoms like vomiting, lethargy, bleedings, 
abdominal pain and/or show liver enlargement and/or increased haematocrit 
combined with decreased platelet levels are classified as dengue with warning signs. 
These patients are considered at risk for severe disease development. Severe dengue 
is characterized by severe plasma leakage, bleedings, and organ impairment. If not 
Figure 1 Global distribution of Dengue Virus (yellow) and Chikungunya Virus (blue). 
Areas in which both viruses co-circulate are marked in green. The red line represents the 10°C isotherm 
line. Within these zone, the vectors Ae. aegypti and Ae. albopictus can survive. The latter can also adapt 




properly treated patients may develop Dengue shock syndrome [4]. About 500,000 
dengue-infected patients are hospitalized per year, and in approximately 25,000 cases 
dengue is fatal [6]. Individuals are life-long protected from disease upon re-infection 
with the same DENV serotype. Remarkably, severe disease is most often seen in 
individuals experiencing a secondary infection with a heterologous DENV serotype 
or in infants born to dengue-immune mothers [7-9]. These observations indicate that 
pre-existing antibodies play an important role in severe disease development, which 
will be discussed in detail in subsequent chapters. Third or tertiary infections on the 
other hand are often mild and usually do not lead to disease manifestations [10]. 
 The global distribution of CHIKV rapidly expanded since the end of 2004. 
Before, only small focal epidemics within Africa and Asia were reported. In only ten 
years, the virus has spread worldwide causing millions of infections in the (sub-)
tropical regions of the world (figure 1)[11,12]. Due to the recent emergence and 
hence naïve population, attack rates of CHIKV are high [13,14]. The first large-scale 
CHIKV outbreak was caused by adaptation of the virus to Ae. albopictus without 
compromising viral fitness in the original vector Ae. aegypti. However, not only 
strains that are primarily transmitted by Ae. albopictus are circulating. For example, 
the ongoing outbreak within the Americas is caused by a CHIKV strain that relies 
on transmission by Ae. aegypti [15]. Importantly, the flexibility in vector usage 
increases the epidemic reach of the virus. In contrast to DENV infection, CHIKV 
infection is in about 75%-95% of the cases symptomatic [16,17]. Affected individuals 
develop Chikungunya fever, which is characterized by high fever, rash, headache, 
myalgia, and arthralgia. Although these symptoms normally resolve within 7-10 
days, a significant number (12%-49%) of patients experience debilitating joint pain 
that can persist from month to years [18,19]. Infection with CHIKV usually leads 
to a protective adaptive immune response with neutralizing antibodies and CD4+ T 
cells being the main antiviral effectors [20,21]. The time intervals between historical 
epidemics have led to the assumption that infection confers long-term, if not life-
long, immunity against re-infection with CHIKV [22,23]. 
 Taken together, both DENV and CHIKV have an enormous health-
economic impact in the affected areas. In spite of continuous effort, no specific 
antiviral treatment or vaccine has been found for either of the viruses and treatment 
is currently focused on relieving the symptoms of disease. For the rational design 
of vaccines and antiviral drugs it is imperative to better understand the dynamic 





Scope of the Thesis
 The research described in this thesis focuses on the early events in DENV 
and CHIKV infection. Both viruses are known to enter the cell via receptor-mediated 
endocytosis and fuse from within acidic endosomes. In this thesis we aimed to further 
investigate the molecular mechanisms that are involved in viral cell entry. Moreover, 
the role of pre-existing immunity on infectivity was assessed using patient serum and 
monoclonal antibodies. 
 Chapter 2 provides an overview of the structure, life cycle and pathogenesis 
of DENV. Infected cells produce DENV particles that vary in maturation state, 
and we and others have demonstrated before that immature virions are essentially 
non-infectious in various cell types [24-26]. The general implementation of this 
finding was however questioned when the receptor molecule DC-SIGN – which 
is also expressed on natural target cells of DENV – had been reported to promote 
the infectivity of both mature and immature West Nile virus, a virus closely related 
to DENV [27,28]. These results prompted us to investigate in chapter 3 whether 
immature DENV is infectious in cells expressing DC-SIGN. To this end, we studied 
the infectious properties of DENV particles of different serotypes and maturation 
states on target cells with and without DC-SIGN. In addition, using the same cell 
types, we examined the role of pre-existing immunity on DENV infectivity in relation 
to DC-SIGN expression.
 In recent years, major efforts have been made to provide insights into the 
route of CHIKV cell entry and the molecular mechanism of membrane fusion. 
Chapter 4 gives a detailed overview on the early events in CHIKV infection. This 
chapter summarizes the current knowledge on viral structure, target cells, entry 
and membrane fusion. In addition, we discuss infection prevention by use of entry 
inhibitors. 
 In chapter 5, we unraveled the cell entry pathway of CHIKV by live-cell 
microscopy. By using fluorescently labeled virions and cellular marker proteins, 
we were able to dissect the route of CHIKV cell entry and unraveled the dynamics 
involved. In addition, we investigated the role of the amino acid at E1-226 in lipid 
dependency of viral entry and membrane fusion. 
 In chapter 6, the membrane fusion characteristics of CHIKV are further 
characterized using liposome-based bulk studies and high-resolution single-molecule 
microscopy. Besides studying basic characteristics like pH- and lipid-dependency of 
fusion, also a detailed kinetic picture of the fusion process is drawn.
 Administration of neutralizing antibodies represents an attractive approach 
to treat or prevent CHIKV infections. Hence, knowledge on the mechanism of 




chapter 7, the generation and in vitro characterization of a panel of CHIKV-specific 
monoclonal antibodies (MAbs) is described. Furthermore, the in vivo activity of 
several highly neutralizing MAbs is assessed in a mouse model. 
 In chapter 8, a series of neutralizing MAbs from the previous chapter are 
tested for their fusion-inhibiting capacities, and the mechanism of neutralization is 
investigated for a selection of fusion-inhibitory antibodies.
 Chapter 9 summarizes and discusses the results obtained in the studies in 
this thesis.
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